Clinical trial
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
NCT00383604
Drugs and interventions used in this trial
0 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No interventions are currently published for this study in CureCurrent. View the original registry record below.
Study at a glance
Registry-backedBreast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Lymphedemaverified · MONDO: lymphedema
Breast Cancerverified · MONDO: breast cancer
Interventions
Sponsors & collaborators
Stanford Universitylead sponsor
California Breast Cancer Research Programcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00383604 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.